×
Skip to content
ShareCafe

  • Home
  • Shares
  • Advice
  • Wealth
    • Wealth Home
    • Product Profiles
  • Property
  • Video
  • Contributors
  • Community
  • About us
  • Facebook
  • Twitter
  • YouTube
  • RSS
Main Menu

Tag: IEL

Broker News

IEL – UBS rates the stock as Buy

July 1, 2020 - by Broker News

IDP Education is highly dependent on international travel but, UBS asserts, the structural thematic is unchanged.

Read More
Shares / Video

Where Are The Opportunities In Australian Small-Caps?

April 30, 2020April 30, 2020 - by Tim McGowen

Sam Twidale, Portfolio Manager for the DNR Capital Australian Emerging Companies Fund, explains why he believes recent volatility in equity markets has provided some excellent opportunities in the smaller cap sector.

Read More
Broker News

IEL – Macquarie rates the stock as Outperform

April 15, 2020 - by Broker News

The broker has reviewed its position on IDP Education post equity raising, envisiging a three-stage recovery beginning with localised lockdowns and travel restrictions extending lower volumes, followed by lockdowns easing but travel restrictions lagging in FY21, and finally normalisation in FY22 with IDP taking market share.

Read More
Broker News

IEL – UBS rates the stock as Upgrade to Buy from Sell

April 3, 2020 - by Broker News

While the next 6-9 months will be challenging, UBS assesses the $190m capital raising and incremental debt facilities provide ample flexibility.

Read More
Shares

Kathmandu, IDP Education Raisings Well Supported By Investors

April 3, 2020April 2, 2020 - by Glenn Dyer

Shares in IDP Education surged more than 20% yesterday after the struggling group raised a lot more money than originally planned. Kathmandu has also completed the institutional component of its deeply discounted $200 million capital raise, raising gross proceeds of around $NZ154 million ($150 million).

Read More
Broker News

IEL – Morgans rates the stock as Upgrade to Add from Hold

April 2, 2020April 2, 2020 - by Broker News

IDP Education was travelling along fine at the beginning of the year before the wheels fell off in March, a trading update revealed. This has prompted a $240m capital raising and debt refinancing. Morgans has cut earnings per share forecast by over -40% and does not expect a full recovery until FY22.

Read More
Shares

In Any Language, English Testing Is A Lucrative Market

November 11, 2019November 11, 2019 - by Tim Boreham

The federal government may have succeeded in cleaning up the woeful private vocational education sector, but now faces a fresh issue in its quest to protect the $35 billion foreign student trade.

Read More
Broker News

IEL – Morgan Stanley rates the stock as Overweight

February 8, 2019 - by Broker News

First half result beat Morgan Stanley’s estimates. Earnings are re-based higher while sales growth assumptions are lifted for FY20 and beyond.

Read More
Broker News

IEL – Morgan Stanley rates as Overweight

May 8, 2018 - by Broker News

Direct competition is limited and highly fragmented so Morgan Stanley believes the company can attain global leadership.

Read More
Broker News

IEL – Morgan Stanley rates the stock as Overweight

May 7, 2018 - by Broker News

Direct competition is limited and highly fragmented so Morgan Stanley believes the company can attain global leadership.

Read More
Broker News

IEL – Morgan Stanley rates the stock as Overweight

January 19, 2018 - by Broker News

Morgan Stanley expects the the company to deliver a strong first half, with earnings certainty underpinned by strong student visa data. IDP continues to be the broker’s preference, notwithstanding it is trading on a higher multiple because of a faster growth trajectory versus Navitas ((NVT)).

Read More
Broker News

IEL – Macquarie rates the stock as Outperform

October 6, 2017 - by Broker News

Macquarie reviews modelling assumptions following additional disclosures in the annual report.

Read More
Broker News

IEL – Macquarie rates the stock as Outperform

October 5, 2017 - by Broker News

Macquarie reviews modelling assumptions following additional disclosures in the annual report.

Read More
Roger Montgomery

IEL & The International Education Boom

September 6, 2017 - by Stuart Jackson

IEL Continues To Profit From The International Education Boom

Read More
Roger Montgomery

IDP Capitalises On Global Demand For A Good Education

February 14, 2017 - by Stuart Jackson

IDP Education (ASX:IEL) is a provider of international student placement and English language testing services. It also owns English language schools in South East Asia and organises educational events and conferences. IDP’s strong result for the six months to December 2016 saw a spike in its share price, and confirmed our faith in this high quality business.

Read More
Broker News

IEL – Macquarie rates the stock as Outperform

February 10, 2017 - by Broker News

First half earnings were ahead of Macquarie’s estimates. The beat on headline net profit reflected gross margin improvement and lower depreciation.

Read More
Broker News

IEL – Macquarie rates the stock as Outperform

January 17, 2017 - by Broker News

IDP has acquired UK-based digital marketing and online student recruitment company Hotcourses, which is basically a global uni/college comparison site. The deal complements IDP’s student placement division and accelerates digital engagement strategies, the broker suggests.

Read More
Roger Montgomery

IDP Leveraging the Growth In Demand For Education

May 25, 2016 - by Stuart Jackson

IDP Education listed on the ASX under the stock code IEL in the latter part of last year.  Education Australia, which comprises 38 Australian Universities owns 50 per cent of IDP, and has agreed to escrow this shareholding until the release of the FY 2016 results in August.

Read More
  • Lunch Report: Energy, mining & bank stocks drag market lower
  • RIO – Macquarie rates the stock as Outperform
  • STO – Citi rates the stock as Downgrade to Neutral from Buy
  • PDL – Morgan Stanley rates the stock as Overweight
  • Australia…One Hour In…ASX down 48 points
  • Morning Report: Key US sharemarkets eased on Friday
  • Netflix Heads US Earnings Reports for the Upcoming Week
  • All Eyes on BHP, Rio Production Numbers

Subscribe to ShareCafe

The daily resource for hands-on investors. Market insights and investment ideas delivered free to your inbox.

Copyright 2020 Informed Investor Pty Ltd ABN 42 162 871 589. All rights reserved.
No portion of this website maybe reproduced, copied or in any way released without written permission.
Share Cafe is a Corporate Authorised Representative (001283561) of PacReef Asset Management Pty Ltd who holds an Australian Financial Services Licence (Number: 488045)

Terms of Service | Financial Services Guide | Privacy Policy | Contact | Advertise

DOWNLOAD RESEARCH REPORT

And a Door Opens Wide

Antisense Therapeutics’ lead drug sits at the nexus of two areas of drug development that are starting to grow dramatically in importance. One relates to its mode of action and the other to the type of drug it is. Combine that with management who know the drug very well and strong results in a trial in a horrible disease afflicting children, and you have the basis for true value creation.

SMSFBrokerFinancial AdviserRetail Investor

Please prove you are human by selecting the Star.


DOWNLOAD RESEARCH REPORT

Fit for tough times; prepared for coal’s upswing

Terracom has counter-cyclically placed itself in a position to improve efficiency and margins plus pursue organic mine growth. Cashflows will further swell once currently depressed coal prices rebound. These assets appear undervalued compared to our Base Case $0.27/share NPV valuation of TER. TER has upside on management’s record of delivering new projects from currently controlled development assets and/or by opportunistically securing acquisitions.

SMSFBrokerFinancial AdviserRetail Investor

Please prove you are human by selecting the Flag.

DOWNLOAD RESEARCH REPORT

A Laser-Like Focus on Adding Value

Since August 1st, Kazia Therapeutics has announced US Food & Drug Administration fast track status for one program & orphan drug and rare paediatric disease designation for another, while finishing the period by announcing a new trial for its cancer drug, paxalisib. Over the next nine months investors are likely to see six data readouts from five programs. How fast can a company go?

SMSFBrokerFinancial AdviserRetail Investor

Please prove you are human by selecting the Tree.